All In Biotech

BLA 761359 · Takeda Pharms USA

Entyvio

Vedolizumab · Intravenous, Subcutaneous

Last checked: Nov 20, 2026Latest source record: Apr 18, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Apr 18, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

126

35 Phase 3, 30 recruiting

FAERS reports

86,807

75,210 serious, 4,311 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • ENTYVIO · VEDOLIZUMAB 300MG · INJECTABLE, INTRAVENOUS · Prescription
  • ENTYVIO · VEDOLIZUMAB 108MG/0.68ML · INJECTABLE, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Vedolizumab" as an intervention, any sponsor and status, largest first.

All 126 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use22,423
  • colitis ulcerative15,710
  • crohn^s disease11,434
  • drug ineffective10,034
  • diarrhoea8,781
  • abdominal pain7,505
  • fatigue6,395
  • haematochezia6,172
  • frequent bowel movements5,300
  • arthralgia4,810
  • malaise4,398
  • nausea4,215

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20111
20121
20131
2014128
20151,680
20162,930
20173,562
20184,739
20195,511
20207,459
202110,537
20229,447
202311,051
202412,187
202511,222
20266,351

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Entyvio (Vedolizumab)

2024 spending

$129M

Beneficiaries

2,863

14,773 claims

Per beneficiary

$45,145

$8,062.78 per unit

View as table
YearSpending
2020$47,057,158
2021$58,917,163
2022$75,974,965
2023$99,999,923
2024$129,249,635

Part B: Entyvio (Vedolizumab) · HCPCS J3380

2024 spending

$769M

Beneficiaries

19,661

117,555 claims

Per beneficiary

$39,134

2024 ASP limit $22.26 per unit

View as table
YearSpending
2020$434,494,107
2021$526,528,197
2022$673,755,475
2023$727,761,505
2024$769,418,664

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 284 on PubMed

Sponsor: Takeda

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.